ArticleMedicine2025
Benefits of alanyl-glutamine and omega-3 PUDAs in postoperative gastroduodenal perforation patients: A single-center retrospective study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This clinical study combined alanyl-glutamine and omega-3 polyunsaturated fatty acids (ω-3 PUFAs) to investigate the effects of parenteral nutrition on postoperative inflammation and nutritional status in patients with gastroduodenal perforation to provide a basis and support for the use of clinical immunonutrients. Patients with gastroduodenal perforations who underwent surgery between January 2018 and December 2023 were included. From the first to the seventh postoperative day, Group A (GA) received conventional postoperative nutrition with fat emulsion (20%), amino acids (17), and glucose (11%) injection; Group B (GB), building on GA's regimen, was additionally treated with 10 g/day of ω-3 PUFAs; and Group C (GC), expanding on GB's regimen, was additionally treated with 10 g/day of alanyl-glutamine. A total of 168 patients were included in the study, with 71 in GA, 30 in GB, and 67 in GC. Total protein and albumin (Alb) levels increased in all 3 groups, with GC showing a more significant increase compared to GB and GA (TP: 7.73 ± 5.00 vs 4.35 ± 5.85 vs 3.92 ± 5.07, P < .05; Alb: 4.07 ± 4.52 vs 1.79 ± 4.00 vs 2.11 ± 4.10, P < .05); C-reactive protein levels decreased in all 3 groups, with the most pronounced decrease in GC (93.71 ± 80.97 vs 72.04 ± 80.48 vs 55.79 ± 83.68, P < .05); the length of hospitalization and among the 3 groups was statistically significant (10.7 ± 2.27 vs 13.39 ± 4.66 vs 12.52 ± 3.46, P < .05), and GB was shorter than GA; the incidence of postoperative complications was significantly lower in GC than in other groups (P < .05). Parenteral nutrition supplemented with alanyl-glutamine and ω-3 PUFAs can increase postoperative total protein and Alb levels, thereby improving patient nutritional status, reducing the production of the inflammatory marker C-reactive protein, mitigating the inflammatory response, and decreasing the incidence of postoperative complications, thus improving patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.